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Abstract
Background—Enteric fever in the United States has been primarily associated with travel and 
with worrisome changes in global patterns of antimicrobial resistance. We present the first 
comprehensive report of National Typhoid and Paratyphoid Fever Surveillance System (NTPFS) 
data for a 5-year period (2008–2012).
Methods—We reviewed data on laboratory-confirmed cases reported to NTPFS, and related 
antimicrobial susceptibility results of Salmonella Typhi and Paratyphi A isolates sent for testing by 
participating public health laboratories to the Centers for Disease Control and Prevention’s 
National Antimicrobial Resistance Monitoring System laboratory.
Results—During 2008–2012, 2341 enteric fever cases were reported, 80% typhoid and 20% 
paratyphoid A. The proportion caused by paratyphoid A increased from 16% (2008) to 22% 
(2012). Foreign travel within 30 days preceding illness onset was reported by 1961 (86%) patients 
(86% typhoid and 92% paratyphoid A). Travel to southern Asia was common (82% for typhoid, 
97% for paratyphoid A). Among 1091 (58%) typhoid and 262 (56%) paratyphoid A isolates tested 
for antimicrobial susceptibility, the proportion resistant to nalidixic acid (NAL-R) increased from 
2008 to 2012 (Typhi, 60% to 68%; Paratyphi A, 91% to 94%). Almost all NAL-R isolates were 
resistant or showed decreased susceptibility to ciprofloxacin. Resistance to at least ampicillin, 
chloramphenicol, and trimethoprim-sulfamethoxazole (multidrug resistant [MDR]) was limited to 
Typhi isolates, primarily acquired in southern Asia (13%). Most MDR isolates were also NAL-R.
Conclusions—Enteric fever in the United States is primarily associated with travel to southern 
Asia, and increasing resistance is adding to treatment challenges. A bivalent typhoid and 
paratyphoid vaccine is needed.
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Each year, typhoid and paratyphoid fever, respectively, cause an estimated 26 million and 5 
million illnesses globally [1]. Both are enteric fevers, which are acute systemic infections 
caused by Salmonella enterica serotypes Typhi and Paratyphi A and B (and rarely C) that 
cause an estimated 215 000 deaths annually [2]. Populations that lack access to potable 
water and adequate sanitation and hygiene are most affected. Incidence is highest in 
southern Asia and sub-Saharan Africa [3]. Paratyphi A infections have increased in Asia, 
with rates surpassing typhoid in some areas [4–7].
Enteric fever is transmitted via the fecal-oral route from people who are acutely infected, 
convalescent, or chronic carriers. It is an acute febrile illness with nonspecific symptoms. 
Systemic complications ranging from intestinal perforation to neurologic manifestations 
have been well documented [8, 9]. Typhoid and paratyphoid fever are clinically 
indistinguishable [10, 11], and bacterial culture remains the gold standard for diagnosis [3]. 
Antimicrobial therapy has reduced typhoid case-fatality rates from 15%–20% to <1% [12].
In the United States, enteric fever has been rare since the 1940s [13–16]. Travelers since 
1970s, especially those returning from southern Asia, have accounted for an increasing 
proportion of cases [13–15]. Vaccination is recommended for US travelers to countries 
where typhoid is endemic [17], but no vaccine against paratyphoid fever is available. 
Resistance to antimicrobial agents has increased in cases diagnosed in the United States, 
reflecting similar changes in southern and southeastern Asia [3, 7, 18]. Multidrug-resistant 
(MDR) Salmonella Typhi, defined as resistance to at least ampicillin, chloramphenicol, and 
trimethoprim-sulfamethoxazole—agents historically used in the United States and other 
countries to treat enteric fever—has been reported in US patients [14, 15, 19]. Treatment 
recommendations include fluoroquinolones (eg, ciprofloxacin) and third-generation 
cephalosporins (eg, ceftriaxone), so the recent emergence of strains with decreased 
susceptibility to fluoroquinolone agents is concerning. Infection with these strains increases 
the cost and complexity of treatment [20, 21].
Typhoid fever has been nationally notifiable in the United States for many years, but 
paratyphoid fever is notifiable only in the general category of “salmonellosis.” In 2008, 
however, the national typhoid surveillance program at the Centers for Disease Control and 
Prevention (CDC) expanded to become the National Typhoid and Paratyphoid Fever 
Surveillance (NTPFS) system. At the same time, the National Antibiotic Resistance 
Monitoring System (NARMS), which already requested Salmonella Typhi and some 
Paratyphi A and C isolates from state public health laboratories, expanded its request to 
include all Paratyphi A and C isolates. We reviewed data from NTPFS and NARMS during 
the first 5 years of expanded surveillance (2008–2012).
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METHODS
Since 1975, state and local health officials have reported typhoid cases to CDC using a 
standard form including patient demographics, clinical information (hospitalization and 
outcome), typhoid vaccination status, and travel history. When paratyphoid fever was added 
to NTPFS in 2008, health departments began reporting cases of enteric fever in which 
serotypes Typhi, Paratyphi A, or Paratyphi C were isolated from a normally sterile site or 
from stool or urine. Paratyphi B infections are not reported to NTPFS because many public 
health laboratories have limited capacity to differentiate serotype Paratyphi B (which is rare 
and causes enteric fever) from serotype Paratyphi B variant L (+) tartrate (+) (previously 
called Salmonella Java, which is common and typically causes gastroenteritis, not enteric 
fever). Patients who traveled outside the United States within 30 days before symptom onset 
are considered to have travel-associated illness. Domestically acquired illness is defined as 
illness in a person without such a travel history.
Countries visited by travelers were grouped by regions based on United Nations criteria 
[22]. Data from the National Trade and Tourism Office (http://travel.trade.gov/
outreachpages/download_data_table/2014_Outbound_Profile.pdf) on numbers of US 
residents traveling to different regions were used to compare the risk of typhoid and 
paratyphoid fever for travelers to each region from which cases were reported. Southern 
Asia was used as the reference, with regions with risk from 0.1 to 0.01 that of southern Asia 
considered as “low” risk and regions with risk from 0.009 to 0.001 that of southern Asia as 
“very low” risk.
The CDC NARMS laboratory uses broth microdilution (Sensititre, Trek Diagnostics, 
Cleveland, Ohio) to determine the minimum inhibitory concentration (MIC) for 14 
antimicrobial agents. We analyzed results for 7 antimicrobial agents most relevant to enteric 
fever treatment: azithromycin (testing began in 2011) and ampicillin, chloramphenicol, 
trimethoprim-sulfamethoxazole, nalidixic acid, ciprofloxacin, and ceftriaxone (testing was 
conducted throughout the review period). Resistance is defined using Clinical and 
Laboratory Standards Institute (CLSI) MIC breakpoints, where available. NARMS methods, 
CLSI classes, and MIC breakpoints are detailed elsewhere [23, 24]. We defined MDR as 
resistance to at least ampicillin, chloramphenicol, and trimethoprim-sulfamethoxazole.
We calculated descriptive statistics for typhoid and paratyphoid A fever cases and compared 
epidemiologic characteristics, risk factors, and antimicrobial resistance patterns; paratyphoid 
C cases were excluded because the numbers were small. We used Pearson exact χ2 tests for 
categorical variables and compared continuous variables using the Wilcoxon rank-sum test. 
Statistical significance was determined at a 2-tailed P value <.05. Statistical analyses were 
conducted using SAS software, version 9.3 (SAS Institute, Cary, North Carolina).
RESULTS
National Typhoid and Paratyphoid Fever Surveillance
During 2008–2012, a total of 2341 enteric fever cases were reported to NTPFS (1872 [80%] 
typhoid, and 469 [20%] paratyphoid A). The proportion caused by paratyphoid A increased 
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from 16% in 2008% to 22% in 2012 (Figure 1). Seasonal patterns were similar for typhoid 
and paratyphoid A, with about one-third of cases reported from July through September 
(typhoid, 35%; paratyphoid A, 34%). All 50 states reported typhoid cases, and 35 states 
reported paratyphoid A cases; the top states for each were California (18% of Typhi, 17% of 
Paratyphi A), New York (14% of Typhi, 12% of Paratyphi A), and New Jersey (8% of Typhi, 
12% of Paratyphi A). Among the 10 states that reported ≥3% of typhoid cases, only Texas 
and Florida did not also report ≥3% of paratyphoid cases.
Patients with typhoid were slightly younger than those with paratyphoid A (median age, 23 
vs 26 years; P = .001); 225 (16%) typhoid patients and 38 (11%) paratyphoid A patients 
were ≤5 years old. Among those, 52 (23%) typhoid patients and 7 (18%) paratyphoid A 
patients were <2 years old. Otherwise, demographic and clinical characteristics were similar 
for typhoid and paratyphoid A cases (Table 1). For both, slightly fewer than half the patients 
were female: 883 (48%) for typhoid, 228 (49%) for paratyphoid A. Although more typhoid 
than paratyphoid A patients were hospitalized for ≥24 hours (typhoid, 77%; paratyphoid A, 
69%), this difference was not statistically significant, and the median duration of 
hospitalization for both was 5 days. Six typhoid patients (<1%) and 2 paratyphoid A patients 
(<1%) died.
Most cases were associated with foreign travel, but the percentage was slightly lower for 
typhoid (86%) than paratyphoid A (92%) (P = .0006). For the 1465 cases in which the 
patient traveled to a single destination (single country), southern Asia was the most common 
destination, accounting for 1206 (82%) typhoid cases and 370 (97%) paratyphoid A cases 
(Table 2). At least 10 typhoid patients each reported travel to other subregions of Asia, 
especially southeastern Asia (including the Philippines and Indonesia); to the western Africa 
subregion (especially Nigeria); and to the Caribbean (especially Haiti and the Dominican 
Republic) and Central America (especially Mexico and Guatemala) subregions of the 
Americas. Using the per-traveler risk in travelers to southern Asia as the reference, travelers 
to Africa and southeastern Asia were in the “low” risk category, and travelers to the 
Caribbean, Central America, eastern Asia, and South America were in the “very low” risk 
category.
US citizens (ie, not visitors or noncitizen US residents) accounted for a lower percentage of 
travel-associated typhoid cases (552/838 [66%]) than paratyphoid A cases (183/231 [79%]) 
(P = .0001). Among those reporting the travel purpose (>1 purpose could be reported), 
visiting friends or relatives was the most common, reported in 966 (85%) of typhoid and 246 
(88%) of paratyphoid A cases. Tourism (typhoid, 95 [11%]; paratyphoid A, 36 [17%]) and 
business travel (typhoid, 79 [9%]; paratyphoid A, 23 [11%]) were also reported. Travelers 
immigrating to the United States during the 30 days before their diagnosis accounted for 113 
(13%) of travel-associated typhoid cases and 1 (6%) of travel-associated paratyphoid A 
cases.
Among travel-associated cases with known typhoid vaccination status, significantly fewer 
typhoid patients than paratyphoid A patients had been vaccinated within 5 years (6% [56/ 
983] vs 23% [45/199]; P < .0001).
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Enteric fever was acquired domestically in 524 (14%) typhoid cases and 36 (8%) 
paratyphoid A cases. Of these, 29 (6%) typhoid cases and 1 (3%) paratyphoid A case were 
related to outbreaks (≥2 epidemiologically related cases). An asymptomatic carrier thought 
to have been the source was identified for 32 (15%) domestically acquired typhoid cases and 
1 (3%) domestically acquired paratyphoid A case.
Antimicrobial Resistance
Antimicrobial susceptibility testing was available for isolates from 1091 (58%) typhoid 
cases and 262 (56%) paratyphoid A cases. Of these, 786 were tested during 2008–2010, 
when the panel did not include azithromycin, and 567 were tested during 2011–2012, when 
azithromycin was included. Specimen sources for Typhi isolates included blood (867 
[79%]), stool (158 [15%]), urine (15 [1%]), and other/unknown sites (51 [5%]). Most 
Paratyphi A isolates were also obtained from blood (226 [86%]); other sources included 
stool (29 [11%]), urine (1 [<1%]), and other/unknown sites (6 [2%]).
Antimicrobial resistance was common. Among Typhi isolates, 314 (29%) were susceptible 
to all clinically relevant antimicrobial agents, 750 (69%) were resistant to nalidixic acid 
(NAL-R) or had decreased susceptibility to ciprofloxacin (NAL-R/DSC), 127 (12%) were 
MDR, and 108 (10%) were both NAL-R/DSC and MDR (Table 3). Among NAL-R Typhi 
isolates, 99% were either resistant or displayed decreased susceptibility to ciprofloxacin. 
One Typhi isolate from a traveler to India had intermediate susceptibility to ceftriaxone, but 
none were resistant. All Typhi isolates tested were susceptibleto azithromycin. NAL-R/DSC 
and MDR were more frequent in Typhi isolates from travel-associated cases. NAL-R/DSC 
was particularly common in isolates from travelers to India (91%) and Bangladesh (93%), 
and NAL-R/DSC with MDR was seen in 53% of isolates from travelers to Pakistan. Overall, 
the percentage of NAL-R/DSC Typhi increased somewhat from 2008 through 2012 (range, 
60%–74%), whereas the proportion of MDR Typhi isolates remained stable (range, 10%–
13%). Susceptibility to all clinically relevant agents was most frequent in isolates from 
travelers to destinations in the Americas.
Susceptibility to all agents was less common for Paratyphi A isolates (n = 13 [5%]) than for 
Typhi. NAL-R/DSC was common in Paratyphi A isolates (246 [94%]; P < .0001), but no 
isolates were MDR. All isolates were susceptible to ceftriax-one, and all tested with 
azithromycin were susceptible. The proportion of NAL-R/DSC Paratyphi A remained 
generally stable from 2008 through 2012 (range, 88%–94%).
Rates and duration of hospitalization were similar regardless of antimicrobial resistance 
pattern. Specifically, for typhoid, hospitalization was reported for 81% (584, median of 5 
days) of patients with NAL-R/DSC infections, 80% (102, median of 6 days) of those with 
MDR infections, and 77% (239, median of 5 days) of those with infections susceptible to all 
clinically relevant agents. Similarly, for paratyphoid A, hospitalization was reported for 72% 
(167, median of 5 days) of patients with NAL-R/ DSC infections and 77% (10, median of 4 
days) of those whose infections were susceptible to all clinically relevant agents.
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Paratyphoid C Cases
Two cases of paratyphoid C were reported (2008 and 2011). The patients were 2 and 6 years 
old, both boys. Neither reported travel outside the United States. One isolate submitted to 
NARMS was susceptible to all agents tested.
DISCUSSION
This review of enteric fever cases diagnosed in the United States from 2008 through 2012 
reveals recent developments that are important for treatment and prevention. The decrease in 
domestically acquired enteric fever observed over recent decades [11, 14] continues, with 
about 90% of cases acquired abroad. Paratyphoid fever, primarily caused by Paratyphi A 
acquired in southern Asia, accounts for a substantial and steadily increasing proportion of 
cases. High rates of antimicrobial resistance, especially in infections acquired in southern 
Asia, pose a continued challenge to effective treatment and highlight the importance of 
prevention.
For years, the proportion of enteric fever cases acquired during international travel has 
increased in the United States [11, 13–15] and in other industrialized countries [20, 25–27]. 
In our 5-year study, 86% of typhoid cases were travel-associated, compared with 79% during 
1999–2006 [14]; the travel-associated percentage was even higher (91%) for paratyphoid 
fever. Careful attention to food and water safety while traveling reduces the risk of typhoid 
and paratyphoid fever [28]. Although we do not have data on whether the patients reported 
here received information on food and water precautions before traveling, it is likely that few 
did. Most patients reported visiting family and friends as the primary reason for travel. 
Surveys of international travelers indicate that most travelers to high-risk regions do not seek 
travel health advice beforehand [29–31] and that those visiting family and friends are even 
less likely than other travelers to do so [32]. In these surveys, respondents who sought 
advice reported that the Internet and primary care physicians were their main information 
sources. Traveler health outreach and education programs, especially programs tailored for 
people visiting family and friends, are needed. Prevention messages available through 
multiple sources including websites, social media, primary health practitioners, and small 
businesses serving immigrant communities may have impact.
Paratyphoid A continues to spread, becoming more common in areas where it is already 
established [6, 33] and emerging in new areas, primarily in Asia [34, 35]. US surveillance 
data reflect both trends—the percentage of cases associated with travel was even higher for 
paratyphoid A than typhoid, as was the percentage of cases linked to travel in Asia. Notably, 
among cases of domestically acquired enteric fever, fewer paratyphoid A than typhoid cases 
were linked to a domestic outbreak. Also, a chronic carrier was less commonly identified in 
investigations of paratyphoid A (3%) than typhoid (15%). These patterns suggest that there 
are fewer carriers of paratyphoid A than typhoid in the United States, which may be due to 
immigration patterns and recent emergence of Paratyphi A. Our data showed similar rates 
and duration of hospitalization and case-fatality rates for paratyphoid A and typhoid. These 
findings are consistent with other recent studies [10, 11].
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We observed concerning increases in antimicrobial resistance [11, 14], particularly in 
resistance to nalidixic acid, a marker of decreased susceptibility or resistance to 
fluoroquinolones such as ciprofloxacin. Although hospitalization rates and durations were 
similar in our data, resistant infections can be associated with greater likelihood of treatment 
failure and pose higher treatment costs [21, 36]. Our review shows patterns of antimicrobial 
resistance linked to specific destinations and consistent with reports from affected countries, 
with NAL-R strains of Typhi and Paratyphi originating mainly in southern Asia [3, 5, 6, 37–
39], and MDR cases originating in southern Asia and Africa [40–42]. Fluoroquinolones are 
recommended for empiric treatment of enteric fever in adults [9], but rates of quinolone 
resistance exceeding 80% in typhoid and paratyphoid A among travelers to southern and 
southeastern Asia suggest that treatment failures will occur. Resistance to ampicillin, 
chloramphenicol, and trimethoprim-sulfamethoxazole (multidrug resistance), agents that 
were widely used for treatment of enteric fever before resistance in Typhi became 
widespread, was seen only in Typhi in our review, not in Paratyphi. Furthermore, our review 
demonstrated that multidrug resistance was relatively stable, probably because these agents 
are now less often used to treat enteric fever. Decreasing multidrug resistance concurrent 
with increasing fluoroquinolone resistance has been reported previously for Typhi [43]. We 
documented no resistance to ceftriaxone or, since testing began in 2011, to azithromycin. 
Both agents are recommended alternatives to fluoroquinolones. Because ceftriaxone and 
azithromycin resistance have been reported from other parts of the world, continued 
surveillance will be important [44].
Despite the availability of 2 licensed typhoid vaccines in the United States and 
recommendations for typhoid immunization before international travel [45], <25% of the 
enteric fever patients had been immunized against typhoid. Improved strategies for 
educating travelers about the availability of typhoid vaccines and the need for pretravel 
vaccination might be helpful. In a 2009–2011 survey, <50% of international travelers 
visiting family and friends had been vaccinated for typhoid [30]. These travelers were also 
more likely than those traveling for other reasons to refuse typhoid vaccine when offered 
[31]. Though effective, available typhoid vaccines have limitations. The protection is 
moderate—about 80% for US travelers [46]. Typhoid vaccines provide no protection against 
Paratyphi A infections, cannot be given to children <2 years old, and provide protection for 
only 2–5 years. Typhoid conjugate vaccines that induce higher levels of immunity, offer 
longer duration of protection, and are included in routine childhood vaccination, as well as 
bivalent vaccines that protect against paratyphoid A, could greatly reduce the burden of 
enteric fever—not only in travelers, but also in residents of countries where typhoid and 
paratyphoid fever are endemic [47–49].
Our data have several limitations besides those already mentioned. Cases of enteric fever not 
reported to state health departments are not reported to NTPFS. Among reported cases, 
epidemiologic and clinical data are largely self-reported by patients during state health 
department case investigations. Some data were missing, and others, such as travel histories, 
may have been inaccurate. Isolates are submitted by state and local public health laboratories 
to NARMS independent of reporting to NTPFS. Due to limitations in identifying 
information submitted with isolates and NTPFS case report forms, we were able to match 
NARMS data to only 58% of typhoid and 56% of paratyphoid A cases. Because of 
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limitations in the data on the number of US travelers, their destinations, and the duration of 
their trips, we provided only comparisons between regions, not specific rates. Finally, 
paratyphoid B was not included.
Although enteric fever in the United States is acquired primarily through travel to endemic 
countries, the few cases in our review that were acquired domestically highlight the small 
but persistent risk of transmission within the United States. Transmission can occur from 
chronic carriers, from acute or convalescent patients, or from eating contaminated foods 
imported from countries in which enteric fever is endemic [16, 45, 50]. Ultimately, because 
enteric fever in the United States is so strongly linked to international travel, elimination will 
only be achieved through efforts to reduce transmission in endemic countries. An integrated 
approach to controlling enteric fever via safe water, improved sanitation, adequate food 
hygiene, and vaccination is needed to achieve this.
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Figure 1. 
Percentage of reported cases of enteric fever due to Salmonella Typhi and Paratyphi A, 
National Typhoid and Paratyphoid Fever Surveillance—United States, 2008–2012.
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Table 1
Demographic and Clinical Characteristics of Patients With Typhoid Fever and Paratyphoid A Fever Reported 
to National Typhoid and Paratyphoid Fever Surveillance, by State—United States, 2008–2012
Characteristic Typhoid Paratyphoid A
Total reported cases, No. 1872 469
Median age, y (range) 23 (0–93) 26 (1–83)
Female 883/1853 (48) 228/467 (49)
US citizen 701/1036 (68) 203/261 (78)
Vaccinateda 61/1176 (5) 47/216 (22)
Travel status
 Travel-associated 1546/1799 (86) 415/451 (92)
 Domestically acquired 253 (14) 36 (8)
Site of isolation
 Blood 1383/1801 (85) 409/457 (87)
 Stool 211/1801 (12) 40/457 (9)
 Other 2 (<1) 0/457 (0)
 Multiple sites 205/1801 (11) 25/457 (5)
Hospitalized 1420/1833 (77) 311/454 (69)
Died 6/1693 (<1) 2/422 (<1)
Data are presented as no./No. (%) unless otherwise specified. Note that typhoid vaccination does not protect against paratyphoid fever.
a
Received typhoid vaccination within 5 years before onset of illness.
Clin Infect Dis. Author manuscript; available in PMC 2017 January 03.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Date et al. Page 13
Table 2
Destinations of Patients With Travel-Associated Typhoid and Paratyphoid A Fever Who Reported Travel to a 
Single Country or United Nations Region or Subregion, National Typhoid and Paratyphoid Fever Surveillance
—United States, 2008–2012
Destinationa Typhoid (n = 1465) Paratyphoid A (n = 382)
Asia 1259 (86) 376 (98)
 Southern Asia 1206 (82) 370 (97)
  India 894 (61) 280 (73)
  Bangladesh 172 (12) 44 (12)
  Pakistan 124 (8) 30 (8)
  Nepal 13 (<1) 14 (4)
  Otherb 3 (<1) 2 (<1)
 Southeastern Asia 41 (3) 4 (<1)
  Philippines 19 (1) 2 (<1)
  Indonesia 11 (<1) 1 (<1)
  Otherc 10 (<1) 1 (<1)
 Other Asian subregionsd 12 (<1) 2 (<1)
Africa 50 (3) 2 (<1)
 Western Africa 37 (3) 2 (<1)
  Nigeria 19 (1) 0 (0)
  Othere 18 (1) 2 (<1)
 Other African subregionsf 13 (<1) 0 (0)
Americas 121 (8) 2 (<1)
 Caribbean 41 (3) 0 (0)
  Haiti 34 (2) 0 (0)
  Otherg 7 (<1) 0 (0)
 Central America 68 (5) 0 (0)
  Mexico 46 (3) 0 (0)
  Guatemala 12 (<1) 0 (0)
  Otherh 10 (<1) 0 (0)
 Other American subregionsi 12 (<1) 2 (<1)
Oceaniaj 9 (<1) 0 (0)
Other regionsk 4 (<1) 2 (<1)
Data are presented as No. (%) of patients.
a
For each region, subregion, and country, totals include travelers who reported travel only to that destination. Destinations to which ≥10 patients 
with either typhoid, paratyphoid A, or both reported travel are included. Because travelers can report travel to >1 country in a single region or 
subregion, numbers at the country level will usually be lower than at the region or subregion levels. Similarly, numbers at the subregion level may 
usually be lower than the regional totals.
b
For typhoid, includes Afghanistan (2) and Sri Lanka (1). For paratyphoid A, includes Sri Lanka (2).
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c
For typhoid, includes Myanmar (3), Vietnam (3), Laos (2), Cambodia (1), Malaysia (1), and Singapore (1). For paratyphoid A, includes Myanmar 
(1).
d
For typhoid, includes Lebanon (8), Iraq (3), and China (1). For paratyphoid A, includes China (2).
e
For typhoid, includes Ghana (7), Guinea (3), Liberia (2), Senegal (2), Mali (1), Niger (1), Sierra Leone (1), and Togo (1). For paratyphoid A, 
includes Ghana (1) and Sierra Leone (1).
f
For typhoid, includes Egypt (3), Tanzania (3), Burundi (2), Cameroon (1), Central African Republic (1), Kenya (1), Uganda (1), and Zimbabwe 
(1).
g
For typhoid, includes Dominican Republic (7).
h
For typhoid, includes El Salvador (9) and Panama (1).
i
For typhoid, includes Peru (7), Ecuador (2), Bolivia (1), Canada (1), and Columbia (1). For paratyphoid A, includes Canada (1) and Brazil (1).
j
For typhoid, includes Marshall Islands (6), Samoa (2), and Australia (1).
k
For typhoid, includes Iceland (3) and Russia (1). For paratyphoid A, includes France (1) and Italy (1).
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